Abstract
PURPOSE: Glycolytic production of HDO from the metabolism of perdeuterated glucose provides a means for metabolic imaging with (2) H MRI. The present study compared HDO production from a cost-efficient [2,3,4,6,6- (2) H (5) ]glucose with [ (2) H (7) ]glucose in vitro and in vivo . METHODS: (2) H NMR spectroscopy was performed to measure glucose consumption, lactate, and HDO production in the SFxL glioblastoma cell line. In vivo studies in healthy mice using (2) H magnetic resonance spectroscopy were performed at 11.1 T after administering a bolus of either metabolic contrast agent. In vivo metabolite levels were quantified using unlocalized and slice-selective localized spectra. RESULTS: Our in vitro results demonstrated similar glucose consumption and HDO production kinetics, although significant differences in lactate labeling were observed. The in vivo study showed comparable glucose consumption and HDO production kinetics following tail-vein bolus administration of either metabolic contrast agent, while lactate was not detected in the brain. CONCLUSION: [2,3,4,6,6- (2) H (5) ]glucose shows comparable HDO production to [ (2) H (7) ]glucose, while offering lower cost and reduced spectral complexity. These findings place [2,3,4,6,6- (2) H (5) ]glucose as an alternative to [ (2) H (7) ]glucose for HDO-based DMI studies.